drugset / Trial / NCT04120766

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

NCT04120766

Phase 2 Active not recruiting 64 enrolled Gregory Jicha, MD, PhD National Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Widespread recognition of the current and projected impact of the dementia epidemic has spurred research into novel drug discovery efforts. It is well recognized by most that Alzheimer's disease is not the only form of dementia and that beginning to turn attention to other disease states is critically important in order to alleviate this burden on the elderly population today This proposal seeks to further progress in this area through the repurposing an existing drug therapy as a potential treatment for Hippocampal Sclerosis of Aging. This disease is seldom recognized clinically and yet is the number one Alzheimer's disease mimic the confounds are diagnostic and treatment of subjects suffering from dementia and as of yet has no potential therapeutic interventions identified. As such, the proposed study represents a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that may hold promise for global efforts targeting late life dementia which is a major health priority in America today.

Timeline

Start
2021-12-01
Primary completion
2026-09-01
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicorandil Other / unclassified 20 mg